OTCMKTS:ATRX Adhera Therapeutics (ATRX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ATRX Stock Alerts $0.0075 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0075▼$0.007550-Day Range$0.0060▼$0.016852-Week Range$0.01▼$0.35Volume2,001 shsAverage Volume112,418 shsMarket Capitalization$87,086.23P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Adhera Therapeutics alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Adhera Therapeutics Stock (OTCMKTS:ATRX)Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Read More ATRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRX Stock News HeadlinesJanuary 30, 2024 | investing.comAdhera Therapeutics Inc (ATRX)August 24, 2023 | seekingalpha.comATRX Adhera Therapeutics, Inc.April 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 22, 2023 | seekingalpha.comIntensity Therapeutics upsizes proposed IPO to $15M from $8MFebruary 27, 2023 | finance.yahoo.comAdhera Therapeutics, Inc. (ATRX)January 25, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 18, 2023 | seekingalpha.comCGTX Cognition Therapeutics, Inc.December 5, 2022 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 9, 2022 | benzinga.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsSeptember 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistSeptember 19, 2022 | seekingalpha.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinMay 19, 2022 | seekingalpha.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersNovember 8, 2021 | finance.yahoo.comAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsOctober 20, 2021 | apnews.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...October 20, 2021 | finance.yahoo.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsOctober 16, 2021 | apnews.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...October 15, 2021 | finance.yahoo.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s DiseaseOctober 4, 2021 | finance.yahoo.comAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasSeptember 15, 2021 | insidermonkey.com5 Penny Stocks with Upcoming Growth CatalystsSeptember 13, 2021 | apnews.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...September 13, 2021 | finance.yahoo.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsSee More Headlines Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATRX CUSIPN/A CIK737207 Webadherathera.com Phone919-518-3748Fax206-830-9424Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,110,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-5,805.73% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.02) per share Price / Book0.00Miscellaneous Outstanding Shares11,630,000Free Float8,348,000Market Cap$87,108.70 OptionableNot Optionable Beta-0.15 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Andrew Albert Kucharchuk M.B.A. (Age 43)Vice Chairman, COO, Acting CFO & Chief Business Officer Comp: $285kKey CompetitorsWellness Center USAOTCMKTS:WCUIGenerex BiotechnologyOTCMKTS:GNBTPraxsynOTCMKTS:PXYNScopus BioPharmaNASDAQ:SCPSAmarantus BioScienceOTCMKTS:AMBSView All Competitors ATRX Stock Analysis - Frequently Asked Questions How have ATRX shares performed in 2024? Adhera Therapeutics' stock was trading at $0.03 at the beginning of the year. Since then, ATRX stock has decreased by 75.0% and is now trading at $0.0075. View the best growth stocks for 2024 here. When did Adhera Therapeutics' stock split? Shares of Adhera Therapeutics reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Adhera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Adhera Therapeutics? Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
